Danske Bank A S Buys 107,858 Shares of Insmed, Inc. $INSM

Danske Bank A S lifted its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 4,494.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 110,258 shares of the biopharmaceutical company’s stock after acquiring an additional 107,858 shares during the period. Danske Bank A S’s holdings in Insmed were worth $19,189,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. EULAV Asset Management purchased a new stake in Insmed during the third quarter valued at about $12,961,000. Artisan Partners Limited Partnership boosted its position in Insmed by 49.0% during the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after buying an additional 1,623,342 shares during the period. Atika Capital Management LLC purchased a new stake in Insmed during the third quarter valued at about $13,681,000. Nisa Investment Advisors LLC boosted its position in Insmed by 374.6% during the third quarter. Nisa Investment Advisors LLC now owns 10,466 shares of the biopharmaceutical company’s stock valued at $1,507,000 after buying an additional 8,261 shares during the period. Finally, Nordea Investment Management AB purchased a new stake in Insmed during the fourth quarter valued at about $3,492,000.

Insmed Trading Down 2.3%

INSM opened at $133.26 on Friday. The business has a 50 day simple moving average of $147.89 and a two-hundred day simple moving average of $166.21. The firm has a market capitalization of $28.76 billion, a price-to-earnings ratio of -20.79 and a beta of 0.90. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. Insmed, Inc. has a one year low of $63.81 and a one year high of $212.75.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. During the same period in the previous year, the company earned ($1.32) EPS. The company’s revenue for the quarter was up 152.6% on a year-over-year basis. Analysts predict that Insmed, Inc. will post -2.51 EPS for the current year.

Insiders Place Their Bets

In other Insmed news, CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $143.97, for a total value of $1,540,335.03. Following the completion of the sale, the chief executive officer directly owned 301,185 shares in the company, valued at $43,361,604.45. This trade represents a 3.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 88,060 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the sale, the chief operating officer owned 106,810 shares of the company’s stock, valued at $17,584,130.30. This trade represents a 45.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 179,777 shares of company stock worth $28,252,720 over the last three months. Company insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Insmed in a research report on Monday, March 16th. They set a “buy” rating and a $228.00 price target for the company. Roth Mkm reissued a “buy” rating and issued a $212.00 target price on shares of Insmed in a research note on Friday, April 17th. Morgan Stanley raised Insmed from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $166.00 to $212.00 in a research report on Monday, March 30th. Royal Bank Of Canada upped their price target on Insmed from $212.00 to $216.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Insmed has a consensus rating of “Buy” and a consensus target price of $213.23.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.